Hangzhou Yili Pharmaceutical

Hangzhou Yili Pharmaceutical is a clinical-stage biopharmaceutical company based in Hangzhou, China, focused on the discovery and development of innovative small molecule drugs. The company primarily targets metabolic diseases and oncology, with a lead program, YL-90148, currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Yili Pharmaceutical's oncology pipeline includes candidates targeting the TGF-beta and adenosine pathways, such as YL-13027 and YL-15293, which are designed to modulate the tumor microenvironment. Founded by industry veterans with experience at global pharmaceutical firms, the company aims to provide high-quality, affordable innovative medicines for patients worldwide.